.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,524,484

« Back to Dashboard

Details for Patent: 7,524,484

Title:Delivery of diphenhydramine through an inhalation route
Abstract: The present invention relates to the delivery of diphenhydramine through an inhalation route. In a composition aspect of the present invention, a composition of a diphenhydramine condensation aerosol is presented. In a method aspect of the present invention, diphenhydramine aerosol is formed by: a) heating a thin layer of diphenhydramine on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% degradation product and an aerosol having an MMAD less than 3 microns. In a kit aspect of the present invention, a kit for delivering a condensation aerosol is provided which comprises: a) a thin coating of diphenhydramine; and b) a device for dispensing the diphenhydramine as an aerosol.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:Jun 30, 2006
Application Number:11/479,361
Claims:1. A condensation aerosol for delivery of diphenhydramine formed by heating a composition containing diphenhydramine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diphenhydramine and less than 5 percent by weight of diphenhydramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0.

4. A method of forming a diphenhydramine containing aerosol comprising: (a) heating a composition containing diphenhydramine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of diphenhydramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

6. The method according to claim 5, wherein the coated composition comprises at least 10 percent by weight of diphenhydramine.

7. A method of forming a diphenhydramine containing aerosol comprising: (a) heating a composition containing diphenhydramine and a pharmaceutically acceptable coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diphenhydramine and less than 5 percent by weight of diphenhydramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

8. The method according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

9. The method according to claim 8, wherein the coated composition comprises at least 10 percent by weight of diphenhydramine.

10. A method of forming a diphenhydramine containing aerosol comprising: (a) heating a composition containing a salt form of diphenhydramine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diphenhydramine and less than 5 percent by weight of diphenhydramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

11. The method according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

12. The method according to claim 11, wherein the coated composition comprises at least 10 percent by weight of the salt form of diphenhydramine.

13. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

14. The method according to claim 5, wherein the condensing comprises allowing the vapor to cool.

15. The method according to claim 8, wherein the condensing comprises allowing the vapor to cool.

16. The method according to claim 11, wherein the condensing comprises allowing the vapor to cool.

17. A method of forming a diphenhydramine containing aerosol comprising: (a) heating a composition containing diphenhydramine coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of diphenhydramine and less than 5 percent by weight of diphenhydramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

18. The method according to claim 17, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

19. The method according to claim 18, wherein the condensation aerosol is formed at a rate greater than 1 mg/second.

20. The method according to claim 19, wherein the condensation aerosol is formed at a rate greater than 2 mg/second.

21. The method according to claim 17, wherein the condensing comprises allowing the vapor to cool.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc